Ricevi le ultime notizie sulle azioni TG Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di TGTX

Ultime notizie per

TG THERAPEUTICS INC

TG Therapeutics

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

TG Therapeutics Inc

News

Press Releases

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

Earnings

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Health Care

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

TGTX

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Abivax

Arcellx

Akero Therapeutics

Alkermes

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Caris Life Sciences

CRISPR Therapeutics

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Krystal Biotech

Kymera Therapeutics

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Jyong Biotech

Merus

Metsera

Nuvalent

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Avidity Biosciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

B. Riley Securities

JP Morgan

Goldman Sachs

Comments

TG Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO